These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 26845589

  • 21. Recent Developments in Pharmacotherapy of Alcoholism.
    Soyka M, Lieb M.
    Pharmacopsychiatry; 2015 Jul; 48(4-5):123-35. PubMed ID: 25761458
    [Abstract] [Full Text] [Related]

  • 22. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB.
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [Abstract] [Full Text] [Related]

  • 23. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
    Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.
    Clin Drug Investig; 2018 Feb; 38(2):147-155. PubMed ID: 29080208
    [Abstract] [Full Text] [Related]

  • 24. Evaluation in alcohol use disorders - insights from the nalmefene experience.
    Naudet F, Palpacuer C, Boussageon R, Laviolle B.
    BMC Med; 2016 Aug 18; 14(1):119. PubMed ID: 27534932
    [Abstract] [Full Text] [Related]

  • 25. Nalmefene: a review of its use in the treatment of alcohol dependence.
    Keating GM.
    CNS Drugs; 2013 Sep 18; 27(9):761-72. PubMed ID: 23949908
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Opioid antagonists for alcohol dependence.
    Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD001867. PubMed ID: 21154349
    [Abstract] [Full Text] [Related]

  • 29. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
    Drobes DJ, Anton RF, Thomas SE, Voronin K.
    Neuropsychopharmacology; 2003 Apr 08; 28(4):755-64. PubMed ID: 12655322
    [Abstract] [Full Text] [Related]

  • 30. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
    Higuchi S, Takahashi M, Murai Y, Tsuneyoshi K, Nakamura I, Meulien D, Miyata H.
    Psychiatry Clin Neurosci; 2020 Aug 08; 74(8):431-438. PubMed ID: 32359104
    [Abstract] [Full Text] [Related]

  • 31. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
    Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.
    Alcohol Clin Exp Res; 1994 Oct 08; 18(5):1162-7. PubMed ID: 7847600
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
    Sinclair J, Chick J, Sørensen P, Kiefer F, Batel P, Gual A.
    Eur Addict Res; 2014 Oct 08; 20(5):209-17. PubMed ID: 24557083
    [Abstract] [Full Text] [Related]

  • 34. Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.
    Hashimoto N, Habu H, Takao S, Sakamoto S, Okahisa Y, Matsuo K, Takaki M, Kishi Y, Yamada N.
    Drug Alcohol Depend; 2022 Apr 01; 233():109365. PubMed ID: 35228081
    [Abstract] [Full Text] [Related]

  • 35. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis - Comment to Naudet.
    Soyka M, Friede M, Schnitker J.
    Pharmacopsychiatry; 2016 Nov 01; 49(6):261-262. PubMed ID: 27388713
    [No Abstract] [Full Text] [Related]

  • 36. Opioid antagonists for alcohol dependence.
    Srisurapanont M, Jarusuraisin N.
    Cochrane Database Syst Rev; 2002 Nov 01; (2):CD001867. PubMed ID: 12076425
    [Abstract] [Full Text] [Related]

  • 37. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
    Yéléhé-Okouma M, Martini H, Lemarié J, Labroca P, Petitpain N, Gibaja V, Paille F, Gillet P.
    Fundam Clin Pharmacol; 2017 Oct 01; 31(5):574-579. PubMed ID: 28322465
    [Abstract] [Full Text] [Related]

  • 38. The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients.
    François C, Rahhali N, Chalem Y, Sørensen P, Luquiens A, Aubin HJ.
    PLoS One; 2015 Oct 01; 10(6):e0129289. PubMed ID: 26053024
    [Abstract] [Full Text] [Related]

  • 39. Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
    Mueller S, Luderer M, Zhang D, Meulien D, Brach BS, Schou MB.
    Alcohol Alcohol; 2020 Feb 07; 55(1):63-70. PubMed ID: 31713583
    [Abstract] [Full Text] [Related]

  • 40. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
    Aubin HJ, Reimer J, Nutt DJ, Bladström A, Torup L, François C, Chick J.
    Eur Addict Res; 2015 Feb 07; 21(3):160-168. PubMed ID: 25832297
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.